-+ 0.00%
-+ 0.00%
-+ 0.00%

Crinetics Pharmaceuticals Doses First Patient in Phase 1/2 Trial of CRN09682 for Neuroendocrine Tumors

路透·12/03/2025 13:00:48

登录查看新闻详情